Keeping Up with Treatment

When you have Pompe disease, your body does not produce enough of the acid alfa glucosidase (GAA) enzyme on its own. When administered by intravenous infusion every two weeks, Lumizyme® (alglucosidase alfa) provides the body with an ongoing source of that enzyme. That’s why it’s very important that you follow your doctor's instructions regarding your Lumizyme therapy.

Lumizyme may not be the only aspect of your Pompe treatment. Talk to your doctor before you add or stop taking any other medications, or make any other changes to your healthcare routines.

Lumizyme patient

Scheduling Your Infusions

Regular Lumizyme infusions every two weeks as prescribed by your doctor are an important part of your treatment program. If you must miss an infusion, talk to your doctor about rescheduling the appointment as soon as possible.

Infusions are likely to be scheduled when you have work, school, or other obligations. If so, you may decide to inform your employer, teacher, or others about your Pompe disease and the importance of following your doctors recommendations for infusions. This is a personal decision that you might want to discuss with your doctor. Online educational resources, patient organizations, and your Sanofi Genzyme Case Manager can also help you in preparing for these conversations.

Planning Ahead

If you will be traveling during your scheduled infusion or you are planning a permanent move, talk to your doctor or your Sanofi Genzyme Case Manager about the potential for arranging an infusion at your destination or new home. Here are some other tips to keep in mind when traveling or moving:

  • Plan well in advance of travel or a move, to ensure enough time to find a qualified facility and arrange treatment
  • Check to see that your insurance will cover your care wherever necessary
  • Speak with your Sanofi Genzyme Case Manager if you need assistance with making arrangements

Learn more about support available through Sanofi Genzyme Support Services


LUMIZYME® (alglucosidase alfa) is an enzyme replacement therapy for patients with Pompe disease (acid α-glucosidase (GAA) deficiency).


  • If you or your child is taking Lumizyme, you should know that severe and potentially life-threatening allergic-type reactions known as anaphylaxis or severe hypersensitivity reactions, and other severe reactions related to the immune system may occur during and after Lumizyme treatment. Reactions may include, for example, kidney dysfunction, extreme difficulty breathing, shallow breathing, abnormal heart rate, low blood pressure, or throat tightness (including face, tongue and lip swelling) and skin lesions.
  • If you or your child experiences these severe reactions, you may require close observation during and after Lumizyme administration. You should discuss with your physician the signs and symptoms of anaphylaxis and hypersensitivity reactions and seek immediate medical care should they occur. Anaphylaxis or severe hypersensitivity reactions are potentially very dangerous. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide immediate medical care. Appropriate medical support measures may be administered when you are being infused with Lumizyme.
  • If your child has a current respiratory condition or illness and has compromised breathing or heart function due to Pompe disease, there may be risk of acute worsening of heart and/or lung function with Lumizyme due to the fluid of the infusion, and your doctor may decide that close observation during and after Lumizyme administration may be necessary.


Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide you with immediate medical care. Appropriate medical support and monitoring measures should be available during infusion.

Immune-Mediated Reactions: You or your child may be monitored for the development of systemic immune-mediated reactions while receiving Lumizyme. If these reactions occur, your doctor may discontinue the infusion and initiate appropriate medical treatment.

Risk of Acute Cardiorespiratory Failure: Infant Pompe patients with heart or breathing problems who are experiencing an acute respiratory condition may be at risk for increasing the seriousness of these problems as a result of Lumizyme administration due to the infusion fluid, and your child’s doctor may require additional monitoring for these infants.

Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for Lumizyme infusion. Ventricular arrhythmias and slow heart rate resulting in cardiac arrest or death have been observed in infant Pompe patients with cardiac hypertrophy during general anesthesia for central venous catheter placement. Appropriate medical support and monitoring measures should be available during infusion.

Risk of Antibody Development: Since Lumizyme is a protein, it is the possible that patients receiving it develop antibodies. Some patients who develop high IgG antibody levels that last for a while may have reduced response to Lumizyme. Patients should be monitored for IgG antibody formation every 3 months for 2 years and then annually thereafter.


The most frequently reported adverse reactions during Lumizyme studies in patients were allergy reactions and included: anaphylaxis, rash, fever, flushing/feeling hot, hives, headache, excessive sweating, nausea, cough, less oxygen in the blood, fast heart rate, rapid breathing, chest discomfort, dizziness, muscle twitching, agitation, bluish or purple skin, redness of skin, high blood pressure/increased blood pressure, facial paleness, chills, tremor, vomiting, fatigue, and muscle pain.


If you are pregnant, you should use Lumizyme only if your doctor has determined that its use outweighs any risks to your unborn child.

You may report side effects to the FDA at 1-800-FDA-1088.

Please see the Full Prescribing Information for complete details, including boxed WARNING.

Product Information

Download this document for more details on Lumizyme, its indication, safety information, and its usage: